4.6 Review

Development of new therapeutic options for the treatment of uveal melanoma

Journal

FEBS JOURNAL
Volume 288, Issue 21, Pages 6226-6249

Publisher

WILEY
DOI: 10.1111/febs.15869

Keywords

C‐ met inhibitors; drug therapy; EGFR inhibitors; HDAC inhibitors; immunotherapy; MEK inhibitors; uveal melanoma

Funding

  1. Equity Fellowship of the University of Sydney
  2. University of Sydney-Wepon post-graduate scholarship
  3. Young Talent's Subsidy Project in Science and Education of the Department of Public Health of Jiangsu Province [QNRC2016627]
  4. Six Talent Peaks Project in Jiangsu Province [WSW-047]
  5. Six-one Scientific Research Project [LGY2019087]

Ask authors/readers for more resources

Uveal melanoma is the most common primary intraocular malignancy in adults, with important cytogenetic and genetic risk factors including chromosome 3 monosomy and mutations in GNAQ/GNA11 genes. While most primary UMs are treated with radiotherapy, enucleation may be necessary for large tumours. Despite efforts to utilize targeted therapies and immunotherapies developed for other cancers, effective treatments for UM remain limited. New approaches, such as proteasomal and histone deacetylase inhibitors, show potential for treating UM, but further research and individualized tumor profiling are needed to improve outcomes.
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. Important cytogenetic and genetic risk factors for the development of UM include chromosome 3 monosomy, mutations in the guanine nucleotide-binding proteins GNAQ/GNA11, and loss of the BRACA1-associated protein 1 (BAP 1). Most primary UMs are treated conservatively with radiotherapy, but enucleation is necessary for large tumours. Despite the effectiveness of local control, up to 50% of UM patients develop metastasis for which there are no effective therapies. Attempts to utilise the targeted therapies that have been developed for the treatment of other cancers, including a range of signal transduction pathway inhibitors, have rarely produced significant outcomes in UM. Similarly, the application of immunotherapies that are effective in cutaneous melanoma to treat UM have also been disappointing. Other approaches that have been initiated involve proteasomal inhibitors and histone deacetylase inhibitors which are approved for the treatment of other cancers. Nevertheless, there have been occasional positive outcomes from these treatments in UM. Moreover, combination approaches in UM have also yielded some positive developments. It would be valuable to identify how to apply such therapies efficiently in UM, potentially via individualised tumour profiling. It would also be important to characterise UM tumours to differentiate the potential drivers of progression from those in other types of cancers. The recent identification of novel kinases and metastatic genes in UM tumours makes the development of new UM-specific treatments feasible.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available